Mutations activating the PI3K (phosphoinositide 3-kinase)/Akt signalling pathway and inactivating the TP53 tumour-suppressor gene are common mechanisms that cancer cells require to proliferate and escape pre-programmed cell death. In a well-described mechanism, Akt mediates negative control of p53 levels through enhancing MDM2 (murine double minute 2)-mediated targeting of p53 for degradation. Accumulating evidence is beginning to suggest that, in certain circumstances, PTEN (phosphatase and tensin homologue deleted on chromosome 10)/PI3K/Akt also promotes p53 translation and protein stability, suggesting that additional mechanisms may be involved in the Akt-mediated regulation of p53 in tumours. In the present article, we discuss these aspects in the light of clinical PI3K/Akt inhibitors, where information regarding the effect on p53 activity will be a crucial factor that will undoubtedly influence therapeutic efficacy.
Conference Article| August 11 2014
PI3K/Akt-mediated regulation of p53 in cancer
Aswin G. Abraham;
Eric O’Neill 1
*Cancer Research UK/MRC Oxford Institute, Gray Laboratories, Department of Oncology, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.
1To whom correspondence should be addressed (email@example.com).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
Aswin G. Abraham, Eric O’Neill; PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans 1 August 2014; 42 (4): 798–803. doi: https://doi.org/10.1042/BST20140070
Download citation file: